Background. Children with perinatal human immunodeficiency virus (HIV) infection (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vaccine response or waning immunity. Our objectives were to estimate seroimmunity in PHIV-infected and perinatally HIV-exposed but uninfected (HEU) children and identify predictors of immunity in the PHIV cohort.
immunodeficiency virus (HIV) infection [6] [7] [8] . Live-attenuated MMR vaccine is contraindicated for HIV-infected children with severe immunosuppression, in whom it can cause serious illness [9] . Fortunately, the widespread use of combination antiretroviral therapy (cART) has resulted in improved immunologic status for most HIV-infected children in the United States today [10] . However, HIV-infected children may be susceptible to vaccine-preventable illnesses despite immunization because past or persistent immunologic abnormalities may have led to lower response rates and shorter duration of protective responses following immunization [11] . Unrecognized susceptibility puts this subpopulation at risk of contracting these infections and could contribute to augmenting outbreaks. The goals of the present study were to estimate and compare the prevalences of MMR immunity in perinatally HIV-infected (PHIV) children and in perinatally HIV-exposed but uninfected (HEU) comparison children in a large US cohort and to evaluate independent predictors of current immunity in PHIV children.
METHODS

Pediatric HIV AIDS Cohort Study
The Adolescent Master Protocol (AMP) of the Pediatric HIV AIDS Cohort Study (PHACS) is a prospective cohort study designed to evaluate the effect of HIV infection and antiretroviral therapy (ART) among PHIV youth [9] . Between March 2007 and November 2009, the study enrolled 451 PHIV and 227 HEU children aged 7-15 years, from 15 sites across the United States, including Puerto Rico. Participants were required to have complete lifetime information regarding ART use, plasma HIV RNA concentrations (viral load), and CD4 + T-lymphocyte (CD4) measurements. The protocol was approved by the institutional review board (IRB) at each site and at the Harvard School of Public Health. Written informed consent was obtained from the parent or legal guardian and assent was obtained from child participants, per local IRB guidelines.
Data Collection
Demographic and clinical characteristics of interest included age, sex, race/ethnicity, body mass index (BMI), vaccination history, viral load, CD4 percentage (CD4%), Centers for Disease Control and Prevention (CDC) clinical classification for HIV disease [12, 13] , and prescribed ART. Characteristics were collected through self-report (eg, race/ethnicity), medical chart abstraction (eg, vaccination, immunologic, virologic, and ART characteristics), or physical exam (eg, height and weight). BMI, included as a measure of nutritional status, was calculated as weight in kilograms divided by height in meters squared and expressed as z scores for age and sex [14] . cART was defined as a regimen consisting of at least 3 antiretroviral drugs from at least 2 different drug classes. Sustained cART was defined a priori as receiving cART for at least 3 consecutive months in an effort to exclude participants who may have initiated cART but discontinued due to intolerance or unsuccessful adherence.
Serologic Testing
Repository sera were obtained yearly in the AMP study. Specimens were frozen at ≤ − 70°C in 0.5 mL aliquots. The most recently available serum specimen as of 10 October 2011 was selected for this cross-sectional seroprevalence study, and all serologic testing was performed by the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Rubella and Mumps Testing
Serum specimens were analyzed in duplicate for rubella and mumps immunoglobulin G (IgG) antibodies using commercially available, US Food and Drug Administration-cleared, indirect enzyme-linked IgG immunoassays (Wampole Laboratories, Inc, Princeton, New Jersey). An index standard ratio of at least 1.10 on both runs was considered evidence of seroprotection for rubella and seropositivity for mumps, as no serologic correlate of protection has been defined for mumps.
Measles Plaque Reduction Neutralization Assay
Seroprotection against measles was assessed using a plaque reduction neutralization (PRN) assay, as this method has been clinically validated [15] .
In brief, Vero cell monolayers were infected with a low-passage Edmonston measles virus strain and incubated with serially diluted serum specimens in duplicate. The 50% endpoint titers were interpolated using the Karber method [16] . Measles seroprotection was defined as a PRN titer of >120 milli-international units (mIU) of neutralizing antibody per milliliter of serum relative to World Health Organization II reference serum 66/202 (supplied by National Institute for Biological Standards and Control, South Mimms, United Kingdom) [16] .
Statistical Analysis
The prevalences of measles seroprotection, rubella seroprotection, and mumps seropositivity were compared between PHIV and HEU participants, with 95% exact binomial confidence intervals (CIs) and Fisher exact test. Demographic and clinical characteristics assessed at the times of first and last MMR dose and date of serologic specimen were compared between PHIV and HEU participants using Wilcoxon rank-sum and Fisher exact tests as appropriate. Among PHIV participants, HIV severity measures and ART use were also compared by MMR antibody status. The prevalences of measles seroprotection, rubella seroprotection, and mumps seropositivity were compared by the number of vaccine doses received while on sustained cART with Fisher exact test. Further analyses assessed whether 1 or more (compared to zero) vaccine doses prior to participant exposure to sustained cART modified the relationship between seroimmunity and the number of vaccine doses received while on sustained cART. To identify key sets of covariates that would be most predictive of seroimmunity and to discriminate between children who have seroimmunity and those who may need to be reimmunized, multivariable models for immunity to each virus were built by initially including the number of doses while on sustained cART and subsequently adding covariates 1 at a time by descending order of their univariable c-statistic, which is analogous to the area under the curve in a receiver-operator curve (ie, a measure of discrimination). To obtain an efficient set of independent clinical predictors, covariates were retained if they were significant at α = .05 and did not nullify the significance of any already included predictors. All analyses were conducted using SAS software version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
As of 10 October 2011, 428 PHIV and 221 HEU participants had serum specimens available for serologic testing. A serologic specimen from 1 PHIV participant did not contain a sufficient quantity of serum to be tested in the measles PRN assay; this participant's data was included only in analyses of mumps seropositivity and rubella seroprotection. The 428 PHIV children, compared with the 221 HEU children, were more likely born before 1996 (when cART became available) and had a different racial/ethnic composition (Table 1) . At the time the serologic specimen was obtained, the PHIV children were older (14.6 vs 12.2 years, P < .001) and had a lower BMI z score (0.30 vs 0.85, P < .001). In both groups, 87% had received 2 doses of MMR, but the distribution of MMR doses was different between the groups (P < .001), as PHIV children were more likely to have received >2 MMR doses (8% vs 2%) and less likely to have received 0-1 MMR doses (4% vs 11%). The median interval from last MMR dose to serologic specimen was longer for the PHIV group (9.8 vs 8.0 years, P < .001).
Among the PHIV children, 96% had ever received sustained cART, but only 81% were taking sustained cART at the time serum was obtained; median age of first cART initiation was 3.1 years (interquartile range, 1.1-5.8 years). At the time of serologic specimen, the median CD4% was 34%; 29 (7%) had a CD4% <15%, 278 (65%) had HIV RNA <400 copies/mL, and 108 (25%) were (lifetime) CDC clinical stage C.
The prevalence of measles seroprotection in PHIV children (57% [95% CI, 52%-62%]) was significantly lower (P < .001) than that in HEU children (99% [95% CI, 96%-100%]) ( Figure 1 ). The prevalence of rubella seroprotection in PHIV children (65% [95% CI, 60%-70%]) was also significantly lower (P < .001) than that in HEU children (98% [95% CI, 95%-100%]). Similarly, the prevalence of mumps seropositivity in PHIV children (59% [95% CI, 55%-64%]) was significantly lower (P < .001) than that in HEU children (97% [95% CI, 94%-99%]). When adjusted for age at serologic testing, all 3 comparisons remained highly significant (P < .001) (data not shown).
Among the subset of PHIV children (n = 253) who were receiving sustained cART and had virologic suppression (viral load <400 copies/mL) and no severe immunosuppression (CD4% ≥15%), 164 (65% [95% CI, 59%-71%]) had measles seroprotection, 178 (70% [95% CI, 64%-76%]) had rubella seroprotection, and 161 (64% [95% CI, 57%-70%]) were seropositive for mumps.
Among the 427 PHIV children with measles PRN results, those with measles seroprotection were more likely to have a more recent birth year, earlier age at first initiation of sustained cART, and higher lifetime nadir CD4% (Supplementary Table 1 ). Although there was no difference in the overall number of measles-containing vaccine doses between PHIV children with and without measles seroprotection (P = .677), the number of vaccine doses administered after receiving sustained cART was significantly greater in PHIV children with measles seroprotection compared to those lacking seroprotection (P < .001). At the time of first vaccine dose, time of most recent vaccine dose, and time of the serologic specimen, CD4% was consistently higher, log viral load consistently lower, and prevalence of sustained cART higher in PHIV children with seroprotection compared to those without seroprotection. Whereas nadir CD4% was significantly higher in the PHIV children with measles seroprotection at the time of the serologic specimen, this association was not present at the time of first or most recent vaccine dose. Those with seroprotection were younger (13.8 vs 15.8 years, P < .001) and had a shorter interval from last vaccine dose (8.7 vs 11.0 years, P < .001) but not BMI z score or CDC stage C, at time of serologic specimen.
Most of the univariable results observed for measles seroprotection were similar for rubella seroprotection and mumps seropositivity with the following differences: CD4% at first or last vaccine dose and CD4% nadir and sustained cART at time of serologic specimen collection did not differ between those with and without rubella seroprotection, whereas the distributions of race/ethnicity, number of vaccine doses overall, and BMI did differ between those with and without rubella seroprotection. Sustained cART and log viral load at time of serologic specimen collection did not differ between those with and without mumps seropositivity, but the distributions of race/ethnicity and less advanced CDC category did. Figure 2 shows the prevalence of measles seroprotection by 0, 1, and ≥2 doses of vaccine while on sustained cART. Measles seroprotection was present in 43% (95% CI, 35%-50%), 53% (95% CI, 45%-62%), and 85% (95% CI, 77%-91%), respectively. The same significant dose-response relationship was observed for rubella seroprotection and for mumps seropositivity in relation to the number of vaccine doses received after sustained cART.
To help assess if the number of vaccine doses while receiving sustained cART was a more important determinant of seroimmunity than younger age at first sustained cART initiation, we stratified the number of vaccine doses received while on sustained cART by number of vaccine doses prior to sustained cART ( Table 2 ). The proportions with seroimmunity were higher in those who received more MMR doses after sustained cART regardless of MMR doses received prior to sustained cART. For instance, among those with at least 2 MMR doses after sustained cART, measles seroprotection was present in 85% (82/96) of those with no pre-cART MMR doses and 86% (12/14) of those with at least 1 pre-cART MMR dose.
In multivariable analyses, greater number of vaccine doses while receiving sustained cART and higher nadir CD4% between last vaccine dose and serologic testing were independent predictors of measles seroprotection, with a cumulative c-statistic of 0.742 (Table 3 ). Greater number of vaccine doses while receiving sustained cART, higher nadir CD4% between last vaccine dose and serologic testing, and a shorter interval between last vaccine dose and serologic assessment were independent predictors of mumps seropositivity, with a cumulative c-statistic of 0.675. Similar to mumps, rubella seroprotection was also independently predicted by greater number of vaccine doses while receiving sustained cART, shorter interval between last vaccine dose and serologic assessment, and race/ethnicity (c = 0.734).
DISCUSSION
In this large cohort of PHIV children, the levels of measles and rubella seroprotection and mumps seropositivity were significantly lower than levels in a simultaneously enrolled comparison group of HEU children and markedly lower than population-based studies of healthy US children [17, 18] . Based on this study, one-third to nearly one-half of PHIV children in the United States may be unprotected against these vaccine-preventable diseases. These findings extend and corroborate smaller published studies of reduced levels of immunity to vaccine-preventable diseases in PHIV populations and support currently recommended criteria for revaccination [1, 19] . Of note, nearly all PHIV children in this study had received the full 2-dose series of MMR vaccines, in contrast to other studies in which perinatal HIV infection has been a risk factor for failure to receive recommended immunizations [20] [21] [22] . Despite concerns that HEU children may have subtle immunologic abnormalities that could impair response to vaccines [23, 24] , the rates of seroprotection and seropositivity in the HEU children in this study were extremely high and reassuringly comparable to those in US children in general [17, 18] . Many studies have demonstrated that PHIV children are at higher risk of lack of response, reduced magnitude of response, Figure 1 . Prevalence of measles and rubella seroprotection and mumps seropositivity with 95% confidence intervals, for perinatally human immunodeficiency virus (HIV)-infected children (PHIV) and HIV-exposed but uninfected children (HEU). Abbreviations: cART, combination antiretroviral therapy; MMR, trivalent measles, mumps, and rubella vaccine. a Sustained cART is defined as at least 3 months of consecutive cART. Vaccine doses include MMR and disease-specific monovalent vaccinations. Subjects who were never on at least 3 consecutive months of cART had their vaccine doses (if any) classified as having happened prior to sustained cART. Figure 2 . Prevalence of measles and rubella seroprotection and mumps seropositivity in children with perinatal human immunodeficiency virus infection by number of vaccine doses administered while receiving sustained combination antiretroviral therapy (cART), defined as receiving cART for at least 3 months.
and shorter duration of response to MMR vaccines [25] [26] [27] [28] [29] . More advanced immunosuppression, incomplete plasma HIV suppression, and lack of cART have all been associated with increased risk of poor response to vaccines [19, [30] [31] [32] . In this study, it is not possible to separate contributions of poor initial vaccine response from antibody loss after an adequate vaccine response, because serologic specimens were obtained many years after most vaccine doses were administered. Nonetheless, this group of older children and youths represents the population of PHIV people in the United States [33] , and it is concerning that such high proportions of these youths-including those currently achieving virologic suppression and good immune status on cART-may not be protected against MMR. Determining the factors that help predict which PHIV children and youths are likely not protected against measles, mumps, or rubella can guide approaches to identifying children who are at highest risk. Receipt of cART for at least 3 months before receiving MMR vaccine doses and initiation of cART at an earlier age were important and interrelated predictors of seroprotection. Prior studies have demonstrated that immune responses to vaccines in PHIV children are most similar to responses in healthy children if cART precedes vaccination [34] . In addition, starting cART in infancy permits the normal development and maintenance of the memory B cells, whereas later cART initiation results in impaired number and function of memory B cells [35] .
Early cART initiation should allow for robust response to MMR and other vaccines in the small number of new infant HIV infections that occur in the United States. But for many older children and young adults with perinatal HIV infection, cART was not available when they were young and so MMR vaccine was commonly administered before cART. Overall, about half of children who received no vaccine after sustained cART lacked serologic evidence of immunity to MMR. In contrast, high proportions of children who received at least 2 doses of MMR vaccine after they were on sustained cART had seroprotection to rubella and measles (less so to mumps), although the rates of seroprotection still fall short of protection following Four hundred subjects were analyzed for measles, whereas 401 were analyzed for mumps and rubella. Subjects were lost due to missing information on age at first instance of 3 consecutive months of cART, race/ethnicity, and years from last MMR dose to date of specimen draw.
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; MMR, trivalent measles, mumps, and rubella vaccine; Ref, reference. a Based on type 3 analysis of effects (controlling for other covariates in the multivariable logistic regression model).
b The cumulative c-statistic for overall model predictability was generated at each step during forward selection of covariates into the multivariable models.
c Sustained cART is defined as at least 3 months of consecutive cART.
2 doses of MMR in healthy children. Furthermore, seroprotection after 2 MMR doses during sustained cART was not improved by having also received MMR vaccine doses before cART or the total number of MMR doses, suggesting that seroprotection is most dependent on the MMR doses administered during sustained cART. In predictive modeling, a higher number of MMR vaccine doses while on sustained cART was a consistent and robust predictor of immunity. This finding is consistent with a recent trial that demonstrated relatively high levels of response to MMR revaccination in PHIV children on cART who had received MMR in the past but who lacked seroprotection to measles [19] . These data also support the recently revised recommendations that PHIV children who start cART before their first MMR dose at age 12-15 months can receive the standard 2-dose MMR schedule recommended generally for children, and that PHIV children who started cART at an older age should be assessed for the need for additional MMR vaccination to ensure receipt of 2 doses of MMR after stable cART has been established (unless they have other evidence of immunity) [1] . This study has important limitations and strengths. Participants were not prospectively assigned to experimental vaccine and cART schedules for comparison. Evaluation of immunity was limited to serologic measures and did not address the role of cell-mediated immunity. Some vaccine doses may have been missed, but the very small number of participants-especially those with HIV infection-with <2 MMR vaccine doses suggests that most doses were captured. The limited size of our study cohort precluded us from developing a separate dataset for validation of our predictive model; we hope that other PHIV cohorts can be used to validate our results. The study is strengthened by the large size of the cohort, lack of selection of participants for a study of vaccine-related immunity, inclusion of a relevant control group, and use of the gold-standard PRN methodology for assessing measles seroprotection. The finding of lower odds of rubella immunity in Hispanics compared with black PHIV children merits further study but is consistent with reports of higher rubella antibody titers following rubella vaccine in black compared with Hispanic healthy children [36] .
The control of MMR depends upon ensuring high levels of population immunity. Older children with perinatal HIV infection may contribute to community risk of outbreaks and may be at higher risk of severe disease if they become infected. Prevention of infant HIV infection, early cART for newly HIV-infected infants followed by the standard schedule for MMR immunization, and repeating MMR vaccine doses given to PHIV children before they were receiving sustained cART can prevent these vaccine-preventable infections in this vulnerable population. These data support current CDC recommendations [1] and can inform global policy recommendations.
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